ArticleNature biomedical engineering2022
Spatially resolved in vivo imaging of inflammation-associated mRNA via enzymatic fluorescence amplification in a molecular beacon.
Article in Nature biomedical engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 125 citations in OpenAlex.
- Subcellular Tandem-Activated Signal Amplification for Spatially Precise Molecular Imaging in Mitochondria.Angewandte Chemie (International ed. in English) · 2026Article
- From Static to Dynamic: Fluorescence Imaging Technology Advances Precise Embryo Evaluation.Small methods · 2026Review
- Lock-Open: An AND Logic-Gated, Entropy-Driven DNA Nanowalker for Highly Sensitive Detection of UDG and APE1 Activities in Hepatocellular Carcinoma.Advanced healthcare materials · 2026Article
- Molecular engineering of CRISPR/Cas12a: from activity enhancement to exponential signal amplification.Chemical science · 2026Review
- Engineered CRISPR/Cas12a2 Nanoprobe Imaging in Living Cells for Precise Tumor Diagnosis.Small methods · 2026Article
- Inflammation-specific DNA origami nanodevice for delivery of siRNAs to treat ulcerative colitis.Nature communications · 2025Article
- Renal clearable CRISPR nanosensor targeting mitochondrial DNA mutation for noninvasive monitoring of tumor progression and metastasis.Science advances · 2025Article
- Peroxynitrite Responsive Second Near-Infrared Cyanine DyeChemical & biomedical imaging · 2025Article
- Conformationally Locked Peptide-DNA Nanostructures for CRISPR-Amplified Activity-Based Sensing.Angewandte Chemie (International ed. in English) · 2025Article
- Upgraded circular single-stranded DNA regulators for multiple-input multiple-output gene circuits in mammalian cells.Science advances · 2025Article
- AnNational science review · 2025Article
- Allosteric genetically encoded biosensor for spatiotemporal monitoring of endogenous RNA dynamics in living cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Molecular Engineering of Direct Activated NIR-II Chemiluminescence Platform for In Vivo Chemiluminescence-fluorescence Duplex Imaging.Nature communications · 2025Article
- Targeting APE1: Advancements in the Diagnosis and Treatment of Tumors.Protein and peptide letters · 2025Review
- Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features.Materials today. Bio · 2024Article
- Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy.Nature communications · 2024Article
- Functional Nucleic Acid Probes Based on Two-Photon for Biosensing.Biosensors · 2023Review
- DNA-Driven Dynamic Assembly/Disassembly of Inorganic Nanocrystals for Biomedical Imaging.Chemical & biomedical imaging · 2023Review
- Oncogene-targeting nanoprobes for early imaging detection of tumor.Journal of nanobiotechnology · 2023Review
- Optical and Photoacoustic ImagingChemical & biomedical imaging · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The in vivo optical imaging of RNA biomarkers of inflammation is hindered by low signal-to-background ratios, owing to non-specific signal amplification in healthy tissues. Here we report the design and in vivo applicability, for the imaging of inflammation-associated messenger RNAs (mRNAs), of a molecular beacon bearing apurinic/apyrimidinic sites, whose amplification of fluorescence is triggered by human apurinic/apyrimidinic endonuclease 1 on translocation from the nucleus into the cytoplasm specifically in inflammatory cells. We assessed the sensitivity and tissue specificity of an engineered molecular beacon targeting interleukin-6 (IL-6) mRNA in live mice, by detecting acute inflammation in their paws and drug-induced inflammation in their livers. This enzymatic-amplification strategy may enable the specific and sensitive imaging of other disease-relevant RNAs in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.